Ramos Alonso, EvaPalomino-Antolín, AlejandraBartolini, ManuelaIriepa, IsabelMoraleda, IgnacioDiez-Iriepa, DanielSamadi, AbdelouahidCortina, Carol V.Chioua, MouradEgea, JavierRomero Martínez, Manuel AlejandroMarco-Contelles, José2023-06-172023-06-172019-04-171420-304910.3390/molecules24081503https://hdl.handle.net/20.500.14352/12527We report the synthesis and relevant pharmacological properties of the quinoxalinetacrine (QT) hybrid QT78 in a project targeted to identify new non-hepatotoxic tacrine derivatives for Alzheimer’s disease therapy. We have found that QT78 is less toxic than tacrine at high concentrations (from 100 μM to 1 mM), less potent than tacrine as a ChE inhibitor, but shows selective BuChE inhibition (IC50 (hAChE) = 22.0 ± 1.3 μM; IC50 (hBuChE) = 6.79 ± 0.33 μM). Moreover, QT78 showed effective and strong neuroprotection against diverse toxic stimuli, such as rotenone plus oligomycin-A or okadaic acid, of biological significance for Alzheimer’s disease.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/molecules24081503https://www.mdpi.com/1420-3049/24/8/1503open accessAlzheimer’s diseasecholinesterase inhibitorhepatotoxicitymolecular modelingneuroprotectionquinoxalinesquinoxalinetacrinestacrineNeurociencias (Medicina)Farmacología veterinaria2490 Neurociencias3109.08 Farmacología